Received Nov 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | Z27PB | — |
a 16-year-old female patient was administered an adult dose; a 16-year-old female patient was administered an adult dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult product administered to child in a 16-year-old female patient who received HAV (Havrix) (batch number Z27PB, expiry date 27-AUG-2026) for prophylaxis. On 06-NOV-2025, the patient received the 2nd dose of Havrix. On 06-NOV-2025, an unknown time after receiving Havrix, the patient experienced adult product administered to child (Verbatim: a 16-year-old female patient was administered an adult dose) and overdose (Verbatim: a 16-year-old female patient was administered an adult dose). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 07-NOV-2025 The patient was administered an adult dose which corresponded to a second dose. The reporter wanted to know if there were some safety concerns to take care of. The Vaccine Administration Facility was the same as Primary Reporter.